Where does Nkarta rank among its competitors?

Nkarta ranks 318th amongst 314 active competitors, of which 121 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Nkarta?

Nkarta's top competitors include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Nkarta - 2026 Company Profile & Competitors

Company Details

Developer of allogeneic natural killer cell therapies for autoimmune diseases. This biotechnology organization focuses on engineering immune cells to address B cell-mediated conditions. The research platform utilizes cell expansion and cryopreservation technologies to create off-the-shelf therapies. These treatments are intended to be administered in outpatient clinical settings to eliminate malfunctioning cells. The development pipeline aims to provide alternatives to current therapeutic standards for various systemic and inflammatory conditions.

Key Metrics

Stage

Unfunded

Ranked

318^th among 343 competitors

Similar Companies

Sana Biotechnology & 341 more

View Nkarta's full profile

Nkarta has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nkarta include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Here is the list of Top 10 competitors of Nkarta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
3rd	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
4th	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, 4Bio Capital & 7 others	65/100
5th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	65/100
6th	Sonoma Biotherapeutics 2012, San Francisco (United States), Series B	Developer of T-cell-based therapies for autoimmune and degenerative diseases	$335M	Lilly Asia Ventures, Octagon Capital Advisors ... & 20 others	64/100
7th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
8th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, VenBio & 10 others	64/100
9th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 15 others	63/100
10th	Q32 Bio 2018, Cambridge (United States), Public	Developer of drugs for treating autoimmune disorders	$106M	Atlas Venture, Orbimed & 9 others	63/100
318th	Nkarta Unfunded	Developer of allogeneic natural killer cell therapies for autoimmune diseases	-	-	16/100